^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Dasatinib In Waldenström Macroglobulinemia

Excerpt:
...- Known tumor expression of mutated MYD88 performed by a CLIA certified laboratory....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

IBRUTINIB SHOWS PROLONGED PROGRESSION-FREE SURVIVAL IN SYMPTOMATIC, PREVIOUSLY TREATED PATIENTS WITH MYD88 MUTATED WALDENSTROM'S MACROGLOBULINEMIA: LONG-TERM FOLLOW-UP OF PIVOTAL TRIAL (NCT01614821).

Published date:
05/17/2018
Excerpt:
The 5-year overall survival for all patients was 87%, and 93% and 80% for MYD88MutCXCR4WT and MYD88MutCXCR4Mut patients, respectively (Log-rank p=0.41)...ibrutinib is highly active and produces long-term responses in symptomatic patients with relapsed and refractory WM
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia

Excerpt:
We evaluated 217 consecutive patients with the clinicopathological diagnosis of WM who were symptomatic and received treatment with ibrutinib....Factors associated with a worse PFS were...CXCR4 mutations (HR 3.0, 95% CI 1.5-6.0; p=0.001). Expression of mutated MYD88 (HR 0.01, 95% CI 0.00-0.09; p<0.001)...were associated with a better PFS.
DOI:
10.1182/blood-2018-99-111626